Your chemistry partner for research & development
SONEAS Research is a professional chemical service provider with a pragmatic approach to innovation, enabling us to create opportunities and add value to our clients’ projects. Established in 1996 and having our pilot plant facility commissioned in 2002 we now provide a comprehensive range of chemistry services to support pharmaceutical and fine chemicals development.
Operating from two sites in Budapest – research, analytical laboratories, and an 8,000 m2 facility housing our process R&D labs, kilo lab and pilot plant – we have the skills, knowledge and experience to deliver your materials when you need them.
SONEAS Chemicals is a CMO company operating on 65,000 m2 and capable to provide starting materials, intermediates pharma and non-pharma applications as well as other fine chemical products on commercial scale.
Contact
Illatos út 33.
H-1097 Budapest
Hungary
Tel: +36 1 347 5060
Fax: +36 1 347 5061
Email: info@soneas.com
Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s…
Chronic underfinancing is a common pitfall for many former socialist states and Hungary is no exception. Total health spending ultimately accounted for 8.0 percent of GDP in Hungary in 2014, which…
Mylan Hungary’s Tamas Uri discusses transitioning into both a branded and generic business dedicated company, Mylan’s expansion in Hungary, and how the pharmaceutical industry can be a key player in improving the…
Hungary’s Minister of Foreign Affairs and Trade Péter Szijjártó highlights the significant role that foreign direct investments have played in developing the country’s healthcare and life science sector, while detailing…
György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of…
János Burovincz, Managing Director of Patent, shares his insights on building a company from scratch, the importance of maintaining a diverse portfolio that can quickly adapt to market needs as…
GSK Hungary’s Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in…
Róbert Ésik, President of the Hungarian Investment Promotion Agency (HIPA), shares his insights into what makes Hungary such an attractive destination for foreign direct investment and ways that the agency…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as…
The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also…
The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute…
See our Cookie Privacy Policy Here
